Current Research

Research for inflammatory breast cancer is ongoing. The following advances may still be under investigation in clinical trials and may not be approved or available at this time. Always discuss all diagnostic and treatment options with your doctor.

The latest trend in research is looking at the effectiveness of antibodies combined with chemotherapy for people with inflammatory breast cancer. Trastuzumab combined with chemotherapy is promising for treatment before surgery of people with inflammatory breast cancer with a cancer that has extra copies of HER2. Also, the drug bevacizumab (Avastin), used in combination with the established drugs doxorubicin (Adriamycin, Rubex) and docetaxel (Taxotere), is being evaluated. Bevacizumab is a new drug that works by blocking the growth of new blood vessels that can bring nutrients to the cancer cells, called anti-angiogenesis.